HomeCompareMLCT vs EQR

MLCT vs EQR: Dividend Comparison 2026

MLCT yields 1025.64% · EQR yields 4.73%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MLCT wins by $23506543.49M in total portfolio value
10 years
MLCT
MLCT
● Live price
1025.64%
Share price
$0.20
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$23506543.53M
Annual income
$19,723,609,349,823.79
Full MLCT calculator →
EQR
EQR
● Live price
4.73%
Share price
$58.58
Annual div
$2.77
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$40.5K
Annual income
$3,819.61
Full EQR calculator →

Portfolio growth — MLCT vs EQR

📍 MLCT pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMLCTEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MLCT + EQR cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MLCT pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MLCT
Annual income on $10K today (after 15% tax)
$87,179.49/yr
After 10yr DRIP, annual income (after tax)
$16,765,067,947,350.22/yr
EQR
Annual income on $10K today (after 15% tax)
$401.93/yr
After 10yr DRIP, annual income (after tax)
$3,246.67/yr
At 15% tax rate, MLCT beats the other by $16,765,067,944,103.55/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MLCT + EQR for your $10,000?

MLCT: 50%EQR: 50%
100% EQR50/50100% MLCT
Portfolio after 10yr
$11753271.78M
Annual income
$9,861,804,676,821.70/yr
Blended yield
83.91%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

MLCT
No analyst data
Altman Z
-1.8
Piotroski
2/9
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+20.1% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MLCT buys
0
EQR buys
0
No recent congressional trades found for MLCT or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMLCTEQR
Forward yield1025.64%4.73%
Annual dividend / share$2.00$2.77
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8%
Portfolio after 10y$23506543.53M$40.5K
Annual income after 10y$19,723,609,349,823.79$3,819.61
Total dividends collected$23218513.75M$16.9K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: MLCT vs EQR ($10,000, DRIP)

YearMLCT PortfolioMLCT Income/yrEQR PortfolioEQR Income/yrGap
1← crossover$113,264$102,564.10$11,248$547.57+$102.0KMLCT
2$1,206,878$1,085,685.14$12,701$666.53+$1.19MMLCT
3$12,102,987$10,811,628.23$14,405$814.59+$12.09MMLCT
4$114,279,868$101,329,670.98$16,413$999.84+$114.26MMLCT
5$1,016,469,856$894,190,397.43$18,795$1,232.92+$1016.45MMLCT
6$8,520,740,273$7,433,117,527.67$21,639$1,527.95+$8520.72MMLCT
7$67,350,310,269$58,233,118,176.66$25,057$1,903.80+$67350.29MMLCT
8$502,243,173,894$430,178,341,906.41$29,197$2,385.87+$502243.14MMLCT
9$3,535,452,502,858$2,998,052,306,790.74$34,250$3,008.70+$3535452.47MMLCT
10$23,506,543,527,881$19,723,609,349,823.79$40,467$3,819.61+$23506543.49MMLCT

MLCT vs EQR: Complete Analysis 2026

MLCTStock

Malachite Innovations, Inc., together with its subsidiaries, provides health and wellness products in the United States. It offers a portfolio of approximately 100 novel cannabosides, including glycosylated tetrahydrocannabinol, cannabidiol, cannabidivarin, and cannabinol. The company also develops THC-glycoside (VBX-100), an oral prodrug for the treatment of gastrointestinal diseases, including inflammatory bowel disease and irritable bowel syndrome. In addition, it engages in identifying, investing in, and repositioning environmental situations with a focus on technological innovations and eco-friendly solutions. The company was formerly known as Vitality Biopharma, Inc. and changed its name to Malachite Innovations, Inc. in October 2021. Malachite Innovations, Inc. was incorporated in 2007 and is headquartered in Cleveland, Ohio.

Full MLCT Calculator →

EQRREIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this MLCT vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MLCT vs SCHDMLCT vs JEPIMLCT vs OMLCT vs KOMLCT vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.